

Evoke Neuroscience awarded Breakthrough Technology agreement with Premier

New agreement with Premier for the eVox® System, the medical device that assesses brain function to aid doctors in the diagnosis of cognitive disorders.

NEW YORK, NY, USA, March 29, 2018 /EINPresswire.com/ -- [Evoke Neuroscience](#) has been awarded a group purchasing agreement as a breakthrough technology with [Premier](#). Effective March 1, 2018, the agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for the eVox® System, the medical device that assesses brain function to aid doctors in the diagnosis of cognitive disorders.

“We are thrilled to be recognized by Premier as a Breakthrough Technology,” said John Armstrong, Executive Vice President of Sales at Evoke

Neuroscience. “This Technology Breakthroughs contract recognizes the innovative way that the eVox System aids primary care physicians in their diagnosis of patients with memory loss and other cognitive disorders.”

Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand cognitive health, and more specifically memory, it is important to measure key biomarkers of the brain itself. The eVox® System fulfills the need for objective [memory-related biomarkers](#) that aid in the diagnosis of cognitive diseases such as dementia.

Primary and specialty care physicians can use eVox® to acquire these biomarkers in-house via a non-invasive procedure performed with minimal staff training and time. Doctors should use their professional judgment in determining when the eVox® System is appropriate to aid in diagnosis.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Evoke Neuroscience



The eVox System aids in the diagnosis of cognitive disorders

Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to assess brain health and aid in the diagnosis of memory loss and other cognitive disorders.

Marinela Gombosev
Evoke Neuroscience
9493307215
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.